Pharmaceutical class : Proteasome Inhibitors (PI)
Active compound : Ixazomib
NINLARO, in combination with lenalidomide and dexamethasone, is the 1st and only reimbursed Oral PI-triplet combination.
NRd is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Available dosages & packagings :
- 3 x 4mg
- 3 x 3 mg
- 3 x 2.3mg
Dosing guide & schedule
The recommended starting dose of Ninlaro® is 4mg orally once a week on Days 1, 8, and 15 of a 28-day treatment cycle
Read more on treatment scheme & dose recommandations of Ninlaro® by clicking on the dosing guide
Price list
Click here to view price information Ninlaro®
Publications:
- Moreau P, et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 2016;374(17):1621-34.
Download the Tourmaline-MM1 study by clicking here - Hou J, Jin J, Xu Y. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. J Hematol Oncol 2017.
Download the China Continuation-study by clicking here - Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
Avet-Loiseau H et al. Blood 2017 ; 130(24) :2610-2618
Download the study by clicking here - Final Overall Survival Analysis of the TOURMALINE-MM1 Phase 3 Trial of ixazomib, Lenalidomide, and Dexamethasone in Patients with relapsed or refractory Multiple Myeloma
Richardson et al. Journal of Clin. Oncol 2021 ;39,22 :2430-2442
Download the final analysis of the TOURMALINE-MM1 study by clicking here - Survival benefit of ixazomib lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
Minarik J et al. BMC Cancer 2021 : 21 :73
Download the study by clicking here
C-APROM/BE/NINL/0042